ClinicalTrials.gg
RecruitingNCT07843940Updated Nov 10, 2026

A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

A Phase 1/2 interventional study of Obrixtamig and Pumitamig in Extensive-stage Small Cell Lung Carcinoma and Advanced Small Cell Lung Cancer, sponsored by Boehringer Ingelheim. Recruiting at 27 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Boehringer Ingelheim · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
270th of 550
55 · median 55
Started
2026
with 36 others
Phase 1/2
113 of 629
32 open now
Primary completion
2030-04
later than 164 of 181 live
Registered
629th of 629
by date

Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 270th largest by planned enrollment of the 550 interventional ones that give a count, is one of 37 that started in 2026, is one of 113 in phase 1/2, reaches primary completion later than 164 of the 181 other live ones, and was the 629th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

105 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 629 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig. Another purpose is to check whether the combination study treatment can make tumours shrink. Obrixtamig and pumitamig are being developed to help the immune system fight cancer.

Participants are put into 2 groups. One group gets obrixtamig and pumitamig. The other group gets obrixtamig and pumitamig with standard chemotherapy (carboplatin and etoposide). All study treatments are given as infusions into a vein.

This study does not have a fixed duration. Participants can receive obrixtamig and pumitamig for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.

03

Conditions studied

  • Extensive-stage Small Cell Lung Carcinoma
  • Advanced Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated written in accordance with ICH-GCP and local legislation prior to any trial-specific procedures, sampling, or analyses.
  2. Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the Informed Consent Form (ICF).
  3. Willing and able to comply with scheduled visits, treatment schedule, the planned trial assessments, laboratory tests, restrictions regarding prohibited medications, lifestyle restrictions, and other requirements related to the trial. This includes that they are able to understand and follow trial-related instructions.
  4. or cytologically confirmed Extensive Stage Small Cell Lung Carcinoma (ES-SCLC) [using the AJCC (American Joint Committee on Cancer) tumour node staging system combined with Veterans Administration Lung Study Group (VALG)'s two stage classification scheme].
  5. Prior systemic anti-cancer treatment for ES-SCLC:

    • For Cohort 1 - must have received at least one line of platinum-containing treatment but no more than 2 per local standard of care for the treatment of ES-SCLC.
    • For Cohort 2 - must have received no prior systemic therapy for ES-SCLC. Participants with prior chemoradiotherapy for limited stage (LS)-SCLC must have been treated with curative intent and had a treatment-free interval of at least 6 months after the last chemotherapy, radiotherapy, or chemoradiotherapy before diagnosis of ES-SCLC to be eligible.
  6. At least one outside of the Central Nervous System (CNS) as defined per (RECIST) 1.1. Previously treated lesions after local therapy (radiotherapy, ablation, interventional procedures, etc.) are generally not considered target lesions. If the lesion with prior local treatment is the only measurable lesion, radiologic evidence must be provided to demonstrate disease progression for selection as target lesion (an isolated blastic bone metastasis or a singular central nervous system metastasis should not be considered as a measurable lesion).
  7. Availability of an (except China).
  8. Adequate organ function. Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  1. Serious concomitant disease or medical condition such as neurologic, psychiatric (including substance use disorder), active ulcers (gastrointestinal tract or skin) or laboratory abnormalities that may negatively impact patient safety during trial participation, affect compliance with trial requirements or invalidate assessments relevant for the investigation of the safety and preliminary efficacy of the drugs.
  2. or cytologically confirmed SCLC with combined histology, diagnosis of Merkel cell carcinoma, medullary thyroid carcinoma or neuroendocrine prostate cancer.
  3. Presence of and/or carcinomatous meningitis.
  4. Known to the trial drugs or their , prior severe, life-threatening hypersensitivity reaction(s) to monoclonal antibodies, or significant risk of allergic or anaphylactic reaction(s) to any of the investigated drug products according to the investigator's judgement.
  5. Participants who experienced severe, life-threatening immune-mediated adverse events, e.g. serious Grade 3 or higher immune-mediated adverse event (imAE) or infusion-related reactions, that led to permanent discontinuation while on treatment with immuno-oncology agents.
  6. Persistent toxicity from previous treatments that has not resolved to ≤ (CTCAE) Grade 1 (except for alopecia, asthenia/fatigue, amenorrhea/menstrual disorders, CTCAE Grade 2 peripheral neuropathy, and CTCAE Grade 2 endocrinopathies controlled by replacement therapy, and toxicities, which are considered irreversible but stable for at least 4 weeks, per investigator judgment).
  7. Prior organ or tissue allograft.
  8. History of or active interstitial lung disease, pulmonary fibrosis, organizing pneumonia or non-infectious pneumonitis (any grade) or any other condition resulting in significant impairment in lung function.

Further exclusion criteria apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Combination of obrixtamig and pumitamig in patients with extensive stage small cell lung carcinoma (ES-SCLC) who progressed on or after a platinum-containing first line (1L) treatment or on or after one additional line of therapy (second line (2L) or third line (3L) patients).

    Drug: Obrixtamig · Drug: Pumitamig

  • Experimental
    Cohort 2

    Combination of obrixtamig, pumitamig and chemotherapy (i.e., carboplatin and etoposide) in 1L ES-SCLC patients.

    Drug: Obrixtamig · Drug: Pumitamig · Drug: Carboplatin · Drug: Etoposide

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of treatment-emergent adverse events (AEs) leading to trial medication discontinuation or dose modification

    Time frame: up to 27 months

Secondary outcomes

  1. Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period

    Time frame: up to 27 months

  2. Occurrence of treatment-emergent DLTs

    Time frame: up to 27 months

  3. Occurrence of treatment-emergent adverse events of special interest (AESIs)

    Time frame: up to 27 months

  4. Occurrence of treatment-emergent adverse events (AEs) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥3

    Time frame: up to 27 months

  5. Objective response (OR)

    Defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version 1.1 (based on investigator assessments), from the first investigational medicinal product (IMP) administration until the earliest date of disease progression, death, last evaluable tumour assessment before the start of the next line of anti-cancer treatment, loss to follow-up, or withdrawal of consent.

    Time frame: up to 44 months

  6. Duration of response (DoR)

    Defined as the time from the first documented OR according to RECIST 1.1 until the earliest date of disease progression or death among patients with confirmed objective response based on investigator assessments.

    Time frame: up to 44 months

  7. Disease control (DC)

    Defined as best overall response of complete response (CR) or partial response (PR) or stable disease (SD) where best overall response is defined according to RECIST 1.1 based on investigator assessments, from the first IMP administration until the earliest date of disease progression, death or last evaluable tumour assessment before start of the next line of anti-cancer treatment, loss to follow-up or withdrawal of consent.

    Time frame: up to 44 months

  8. Progression-free survival (PFS)

    Defined as the time from first IMP administration until the earliest date of disease progression according to RECIST 1.1 based on investigator assessments or death from any cause, whichever occurs first.

    Time frame: up to 44 months

07

Study locations

2 of 27 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2030, 42 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 42 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartActual
Oct 1, 2026was Sep 2026
Primary completionEst.
Apr 17, 2030
CompletionEst.
Apr 21, 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
27 sites changed recruiting status (25 now not yet recruiting, 2 now recruiting)
Show 27 sites
  • University of Miami · Miami, United Statesno status→Not yet recruiting
  • Dana-Farber Cancer Institute · Boston, United Statesno status→Not yet recruiting
  • START New Jersey · East Brunswick, United Statesno status→Recruiting
  • New York University Langone Medical Center · New York, United Statesno status→Not yet recruiting
  • SCRI Oncology Partners · Nashville, United Statesno status→Not yet recruiting
  • Chris Obrien Lifehouse · Camperdown, Australiano status→Not yet recruiting
  • Townsville University Hospital · Douglas, Australiano status→Not yet recruiting
  • Cliniques Universitaires Saint-Luc · Brussels, Belgiumno status→Not yet recruiting
  • Universitair Ziekenhuis Gent · Ghent, Belgiumno status→Not yet recruiting
  • Sichuan Cancer Hospital · Chengdu, Chinano status→Not yet recruiting
  • Harbin Medical University Cancer Hospital · Harbin, Chinano status→Not yet recruiting
  • Shanghai Chest Hospital · Shanghai, Chinano status→Not yet recruiting
  • CTR Leon Berard · Lyon, Franceno status→Not yet recruiting
  • HOP Timone · Marseille, Franceno status→Not yet recruiting
  • Institut Gustave Roussy · Villejuif, Franceno status→Not yet recruiting
  • Technische Universität Dresden · Dresden, Germanyno status→Not yet recruiting
  • Universitätsklinikum Essen AöR · Essen, Germanyno status→Not yet recruiting
  • Universitätsklinikum Tübingen · Tübingen, Germanyno status→Not yet recruiting
  • Okayama University Hospital · Okayama, Okayama, Japanno status→Not yet recruiting
  • Kansai Medical University Hospital · Osaka, Hirakata, Japanno status→Not yet recruiting
  • Shizuoka Cancer Center · Shizuoka, Sunto-gun, Japanno status→Not yet recruiting
  • Universitair Medisch Centrum Groningen · Groningen, Netherlandsno status→Not yet recruiting
  • Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza · Brzozów, Polandno status→Not yet recruiting
  • Lower Silesian Oncology Centre · Wroclaw, Polandno status→Not yet recruiting
  • Hospital Clínic de Barcelona · Barcelona, Spainno status→Not yet recruiting
  • Hospital Universitario 12 de Octubre · Madrid, Spainno status→Not yet recruiting
  • Hospital Clinico De Valencia (INCLIVA) · Valencia, Spainno status→Recruiting
across 2 updates, Oct 13, 2026 – Nov 10, 2026
Start date
Sep 24, 2026→Oct 1, 2026 (actual)
moved 2 times, Sep 30, 2026 – Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Harbin Medical University Cancer Hospital · Harbin, ChinaContact removed c•••@bitrialsupport.com · •••0553
Nov 10, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 4 updates
  1. Nov 10, 2026
    Hospital Clinico De Valencia (INCLIVA) is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Harbin Medical University Cancer Hospital · Harbin, ChinaContact removed c•••@bitrialsupport.com · •••0553
    + 1 other change: verification date
  2. Oct 13, 2026
    Not yet recruiting→Recruiting
    27 sites changed recruiting status (26 now not yet recruiting, 1 now recruiting)
    Show 27 sites
    • University of Miami · Miami, United Statesno status→Not yet recruiting
    • Dana-Farber Cancer Institute · Boston, United Statesno status→Not yet recruiting
    • START New Jersey · East Brunswick, United Statesno status→Recruiting
    • New York University Langone Medical Center · New York, United Statesno status→Not yet recruiting
    • SCRI Oncology Partners · Nashville, United Statesno status→Not yet recruiting
    • Chris Obrien Lifehouse · Camperdown, Australiano status→Not yet recruiting
    • Townsville University Hospital · Douglas, Australiano status→Not yet recruiting
    • Cliniques Universitaires Saint-Luc · Brussels, Belgiumno status→Not yet recruiting
    • Universitair Ziekenhuis Gent · Ghent, Belgiumno status→Not yet recruiting
    • Sichuan Cancer Hospital · Chengdu, Chinano status→Not yet recruiting
    • Harbin Medical University Cancer Hospital · Harbin, Chinano status→Not yet recruiting
    • Shanghai Chest Hospital · Shanghai, Chinano status→Not yet recruiting
    • CTR Leon Berard · Lyon, Franceno status→Not yet recruiting
    • HOP Timone · Marseille, Franceno status→Not yet recruiting
    • Institut Gustave Roussy · Villejuif, Franceno status→Not yet recruiting
    • Technische Universität Dresden · Dresden, Germanyno status→Not yet recruiting
    • Universitätsklinikum Essen AöR · Essen, Germanyno status→Not yet recruiting
    • Universitätsklinikum Tübingen · Tübingen, Germanyno status→Not yet recruiting
    • Okayama University Hospital · Okayama, Okayama, Japanno status→Not yet recruiting
    • Kansai Medical University Hospital · Osaka, Hirakata, Japanno status→Not yet recruiting
    • Shizuoka Cancer Center · Shizuoka, Sunto-gun, Japanno status→Not yet recruiting
    • Universitair Medisch Centrum Groningen · Groningen, Netherlandsno status→Not yet recruiting
    • Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza · Brzozów, Polandno status→Not yet recruiting
    • Lower Silesian Oncology Centre · Wroclaw, Polandno status→Not yet recruiting
    • Hospital Clínic de Barcelona · Barcelona, Spainno status→Not yet recruiting
    • Hospital Universitario 12 de Octubre · Madrid, Spainno status→Not yet recruiting
    • Hospital Clinico De Valencia (INCLIVA) · Valencia, Spainno status→Not yet recruiting
    Start date Oct 5, 2026→Oct 1, 2026 (now actual)
    + 1 other change: verification date
  3. Sep 30, 2026
    Start date Sep 24, 2026→Oct 5, 2026
  4. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843940
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Oct 1, 2026
Primary completion
Apr 17, 2030 (estimated)
Completion
Apr 21, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Obrixtamig · Pumitamig

Start the discussion